Reversal of IKZF1-induced glucocorticoid resistance by dual targeting of AKT and ERK signaling pathways

Miriam Butler1,2†, Britt M.T. Vervoort3,1†, Dorette S. van Ingen Schenau1, Lieneke Jongeneel1, Jordy C.G. van der Zwet1, René Marke2, Jules P.P. Meijerink1, Blanca Scheijen3,4, Laurens T. van der Meer1‡ and Frank N. van Leeuwen1*‡

1Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands, 2Laboratory of Pediatric Oncology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands, 3Department of Pathology, Radboud University Medical Center, Nijmegen, Netherlands, 4Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands

Although long-term survival in pediatric acute lymphoblastic leukemia (ALL) currently exceeds 90%, some subgroups, defined by specific genomic aberrations, respond poorly to treatment. We previously reported that leukemias harboring deletions or mutations affecting the B-cell transcription factor IKZF1 exhibit a tumor cell intrinsic resistance to glucocorticoids (GCs), one of the cornerstone drugs used in the treatment of ALL. Here, we identified increased activation of both AKT and ERK signaling pathways as drivers of GC resistance in IKZF1-deficient leukemic cells. Indeed, combined pharmacological inhibition of AKT and ERK signaling effectively reversed GC resistance in IKZF1-deficient leukemias. As inhibitors for both pathways are under clinical investigation, their combined use may enhance the efficacy of prednisolone-based therapy in this high-risk patient group.

KEYWORDS
leukemia, glucocorticoids, IKZF1, therapy resistance, AKT, ERK

Introduction

Despite improvements in up-front treatment regimens and the introduction of immunotherapies, about 10-15% of the pediatric acute lymphoblastic leukemia (ALL) patients develop relapse disease, which remains difficult to treat and almost half of the patients will ultimately succumb to their disease (1–3).
Several genetic aberrations are associated with an increased relapse risk. Deletions or mutations affecting the B-cell transcription factor IKZF1, which occur in 10-15% of pediatric B-cell progenitor ALL (BCP-ALL), were shown to negatively affect cellular responses to a number of therapeutic drugs, thereby increasing the chance of therapy failure (4, 5). Alterations in IKZF1 induce therapy resistance of leukemic cells via distinct mechanisms, including enhanced integrin-dependent survival signaling through activation of focal adhesion kinase (FAK) (6) and increasing cell intrinsic resistance to glucocorticoids (GCs) (7–9).

Synthetic glucocorticoids are a central component of the multi-drug treatment protocols of ALL worldwide. These drugs act by binding to the glucocorticoid receptor (GR), a ligand activated transcription factor located in the cytosol, which translocates to the nucleus to regulate transcription of GR-target genes. Resistance to GCs is recognized as one of the main causes of relapse in ALL (10), and as a result, the initial response to prednisolone is a strong predictor of treatment outcome (11–13). There are several mechanisms that contribute to GC resistance, such as reduced expression or loss of function of the GR, alterations in cellular metabolism, or resistance to apoptosis (e.g. via Bcl2 family members), but restoring GC therapy response has remained challenging (10). We previously showed that IKZF1 alterations confer resistance to GC treatment by inhibition of GC-induced transcriptional responses, but the exact molecular mechanisms underlying these effects remain to be elucidated (7).

Recently, IKZF1 was identified as transcriptional repressor of two PI3K pathway related genes (PIK3CD and PIKFYVE) in T-ALL (14), leading to the induction of AKT signaling in response to IKZF1 loss. In T-ALL, AKT1 activity was shown to be a determinant of GC resistance, driving phosphorylation of the GR to prevent its nuclear translocation and, consequently, glucocorticoid-induced gene expression (15). Indeed, pharmacological inhibition of AKT effectively reversed GC resistance both in vitro and in vivo (15). Also in BCP-ALL there is evidence that AKT signaling can induce GC resistance, as components of the AKT pathway appear to be over-activated in GC-resistant pre-B-ALL samples (16). Moreover, it was shown that CRLF2 rearranged leukemias can be re-sensitized to GCs by targeting of AKT (17). Here, we explored the connection between loss of IKZF1 function, AKT signaling and GC therapy resistance using an isogenic cell line model, normal B cells derived from Iκzf1−/− mice as well patient-derived ALL xenografts.

Methods

Ethical statement

Patient derived xenografts were generated from patient samples collected from different countries within the International BFM Study Group (I-BFM-SG) and the Dutch Childhood Oncology Group. All patients were enrolled in trials on treatment of pediatric ALL conducted by individual member groups of the I-BFM-SG: the AIEOP-BFM study group (Austria, Germany, Italy and Switzerland), the FRALLE study group (France) and the United Kingdom (UK) National Cancer Research Institute (NCRI) Childhood Cancer and Leukemia Group and DOCG Group. All treatment trials were approved by the respective national institutional review boards, and informed consent for the use of spare specimens for research was obtained from study individuals, parents or legal guardians.

Plasmids

The following plasmids were obtained via Addgene: pS-Pax2 (#12260), pMD2.G (#12259), pL-CRISPR.EFS.GFP (#57818), pLKO5.sgRNA.EFS.tRFP (#57823). For targeted knockout, gRNA sequences (Supplemental Table 1) were cloned into pL-CRISPR.EFS.GFP and pLKO5.sgRNA.EFS.tRFP using the BsmBI sites and the sequence integrity was verified using Sanger sequencing.

Reagents

Prednisolone, MK2206, Uprosertib and SCH772984 were purchased from Selleckchem (Munich, Germany) and dissolved as instructed by the manufacturer.

Cell culture

SEM cells (ACC 546) were obtained from the Leibniz Institute DSMZ (German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany) and maintained in RPMI-1640 medium (Invitrogen, Thermo Fisher Scientific, Breda, the Netherlands), supplemented with 10% fetal bovine serum (FBS, Greiner Bio-One, Essen, Germany) and 1% penicillin/streptomycin solution (P/S) (Invitrogen) at a cell density between 0.25 and 3x10⁵ cells per milliliter.

Hek293FT cells were purchased from Invitrogen and maintained in DMEM, supplemented with 10% FBS, 1% non-essential amino acids (Gibco, Thermo Fischer) and 1% P/S. Cell cultures were tested regularly for the presence of mycoplasma.

Cell line identity was confirmed by DNA fingerprinting.

Lentivirus production and transduction

HEK293FT packaging cells (Invitrogen) were transected with a viral backbone encoding the sgRNAs or Cas9 and the helper plasmids for virus production (psPAX2 and pMD2.G) using Polyethylenimine (PEI). Virus containing supernatant was...
collected 2 days after transfection. Virus was concentrated by centrifugation at 25,000G for 1 hour at 4°C and resuspended in the cell culture medium required by the target cells. Target cells (0.5-1x10⁶) were transduced with 1 ml virus (1-10 times concentrated) using spinoculation for 45 min at 700g (30°C) in the presence of 5 ug/ml polybrene (Santa Cruz Biotechnology, Dallas, TX). 72-96 hours after transduction GFP/RFP positive cells were sorted as single cell per well by flow cytometry using a H800S Cell Sorter (Sony Biotechnology). Single cell clones were individually analyzed for evidence of mutations and IKZF1 expression.

**Sanger sequencing**

Genomic DNA was isolated using the Nucleospin genomic DNA isolation kit (#740952, Macherey-Nagel, Bioke, Leiden, the Netherlands). The IKZF1 exon 3 locus was amplified by PCR and cloned into the pGEM-t-easy plasmid (Promega, Madison, WI) and transformed to E.coli. Plasmid DNA was isolated from single colonies using the Nucleospin easypure kit (#740727, Macherey-Nagel) and at least 10 colonies per genotype submitted for Sanger sequencing (Macrogen, Amsterdam, the Netherlands) to ensure sufficient coverage of both alleles.

**RNA sequencing**

RNA sequencing and data analysis was performed by NovoGene (Cambridge, UK) on triplicate samples. mRNA samples from SEM WT and IKZF1+- cells were purified using a RNeasy minikit (#74106, Qiagen, Hilden, Germany) with on column DNase (#79254, Qiagen) treatment. Aberrant splicing was visualized using the Integrative Genomics Viewer (IGV, Broad Institute, Cambridge, MA).

**Cell viability assays**

Cell viability was determined by flow cytometry using amine staining to discriminate between live and dead cells. Cells were seeded in a 96-well plate, in a 24-well plate or in a 6-well plate at 500,000 cells per ml. After the indicated incubation times, cells were stained with LIVE/DEAD™ Fixable Dead Cell Stain Sampler Kit (Thermo-Fischer, L34960) as described previously. Cytogenetic properties of all PDX can be found in Supplemental Table 2.

**RNA sequencing**

RNA sequencing and data analysis was performed by NovoGene (Cambridge, UK) on triplicate samples. mRNA samples from SEM WT and IKZF1+- cells were purified using a RNeasy minikit (#74106, Qiagen, Hilden, Germany) with on column DNase (#79254, Qiagen) treatment. Aberrant splicing was visualized using the Integrative Genomics Viewer (IGV, Broad Institute, Cambridge, MA).

**Cell viability assays**

Cell viability was determined by flow cytometry using amine staining to discriminate between live and dead cells. Cells were seeded in a 96-well plate, in a 24-well plate or in a 6-well plate at 500,000 cells per ml. After the indicated incubation times, cells were stained with LIVE/DEAD™ Fixable Dead Cell Stain Sampler Kit (Thermo-Fischer, L34960) according to the manufacturer’s instructions and analyzed by Fluorescence Activated Cell Sorting (FACS) using a LSRII flow cytometer (BD Biosciences, Breda, The Netherlands) or CytoFLEX LX (Beckman Coulter). For co-culture experiments, MSCs were gated out via FSC/SSC gating. The data were collected and analyzed using FlowJo V10 software (FlowJo, Ashland, Oregon).

**Ex vivo culture of patient-derived xenografts**

Patient-derived xenografts (PDXs) were generated as described before by intra-femoral injection of 1 x 10⁵ to 5 x 10⁶ viable primary ALL cells in NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice (18). The ex vivo co-culture method has been described previously (19). In short, hTERT immortalized MSCs (20) were seeded in a 96-wells format (14,000 cells/well) 24 hours prior to the addition of ALL xenografts (140,000 cells/well). ALL cells were allowed to settle for 24 hours before drugs were added. After 3d of drug incubation, cells were stained with LIVE/DEAD™ Fixable Dead Cell Stain Sampler Kit (Thermo-Fischer, L34960) as described previously. Cytogenetic properties of all PDX can be found in Supplemental Table 2.

**Experimental procedures Ikzf1 knockout animals**

The Ikzf1Neo knockout mouse line that was used in this study was kindly provided by M. Busslinger (Research Institute of Molecular Pathology, Vienna, Austria). The Ikzf1Neo strain was maintained as a heterozygous knockout line (Ikzf1+/-) on an inbred C57BL/6J genetic background, and all animals were housed under specific pathogen-free conditions. All animal experiments were licensed by the Dutch Central Authority for Scientific Procedures on Animals and approved by the Animal Welfare Body of the Radboud university medical center and performed in accordance with institutional and national guidelines. Wild-type and Ikzf1+/- mice were sacrificed at the age of 8 to 14 weeks after which spleens were removed. Single cell suspensions of splenocytes were obtained using a 70 μM cell strainer. Erythrocytes in the isolates were removed by lysis in red blood cell lysis buffer (Sigma-Aldrich, Zwijndrecht, Netherlands). Single cell splenocytes were cultured for 48 hours in RPMI-1640 medium (Life technologies, Carlsbad, CA) supplemented with 10% heat-inactivated fetal calf serum (FCS), 1% penicillin/streptomycin (Invitrogen), and 50 μM β-Mercaptoethanol in the presence of 5 μg/ml lipopolysaccharide (LPS). Stimulated and viable splenic B-lymphocytes obtained after Ficoll gradient purification were subsequently cultured in a 96-well plate at a density of 1x 10⁵ cells/well under similar conditions as in the initial expansion phase. B cells were treated with indicated doses of drugs. After 72 hours, cells were prepared for immunoblotting as stated below.
Real-time quantitative polymerase chain reaction

Total RNA was extracted using a RNeasy mini-kit (Qiagen). Subsequently, cDNA was synthesized using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). mRNA expression levels were determined using a Power SYBR® Green PCR master mix with gene-specific primers (sequences are listed in Supplemental Table 1) and a CFX96 Touch Real-Time PCR detection system (Bio-Rad, Hercules, CA, USA). HPRT mRNA expression was employed as a reference to obtain the fold change in expression levels of target genes using the comparative cycle threshold 2(-ΔΔCt) method. Primer sequences are listed in Supplemental Table 1.

Immunoblotting

Cells were lysed in Laemmli protein buffer and treated with benzonase nuclease (Sigma Aldrich) for 30 minutes, prior to boiling. Purified proteins were separated by SDS-PAGE and transferred to PVDF membranes or nitrocellulose membranes (Amersham Biosciences). After protein transfer, membranes were blocked in TBS-5% elk and incubated with primary antibodies (Staining Biosciences). After protein transfer, membranes were blocked in TBS-0.02% Tween, followed by incubation with an IRDye conjugated secondary antibody (Li-cor, Biotechnology). Proteins were visualized and quantified with the Odyssey® CLx and accompanying Image Studio software (Li-cor, Biotechnology).

Statistical analyses

Statistical analyses for the cell viability, quantified protein expression, and qRT-PCR assays were performed using PRISM6 (GraphPad Software, La Jolla, CA). For most dose-response curves, the shape of the curve did not allow curve fitting and IC50 calculations. Therefore, we calculated the area under the curve and tested differences for significance using a one-way ANOVA and Tukey’s multiple comparisons test. For Western blot quantifications and qRT-PCR a two-sided student’s t test and one-way ANOVA followed by Dunnett’s multiple comparisons test were performed. p-values < 0.05 were considered statistically significant (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).

Results

IKZF1 regulates AKT signaling

CRISPR/Cas9-based genome editing was used to target the IKZF1 locus in SEM pro-B-ALL cells. Since we found a strong selection against cells carrying a heterozygous loss of IKZF1, leading to an instable phenotype (not shown), we used a homozygous knockout model to assess the effects of IKZF1 loss (Figure 1A and Supplemental Figures 1A, B). Similar to what has been observed in primary patient samples, disrupted IKZF1 expression led to increased resistance against prednisolone treatment. Analogous to what has been observed in T-ALL (14), a loss of IKZF1 expression was accompanied by enhanced phosphorylation of AKT, while total AKT protein expression remained unaffected (Figure 1A and Supplemental Figure 2A). To demonstrate that the effect on AKT phosphorylation was a direct consequence of IKZF1 loss, and independent of the leukemic context, we investigated AKT status in LPS-activated B cells from Ikrz1+/- mice (Supplementary Figures 3A, B). Previously, we showed that these cells are about 100-fold more resistant to synthetic GCs compared to B cells derived from Ikrz1 wild-type mice (7). Indeed, similar to Ikrz1+/- SEM cells, enhanced AKT phosphorylation was observed in Ikrz1+/- B cells as compared to wild type B cells isolated from control (Supplementary Figure 3B).

Inhibition of AKT signaling partly restores GC-sensitivity in IKZF1+/- BCP-ALL cells

To test whether AKT functions as a mediator of GC resistance in IKZF1-deficient BCP-ALL cells, we treated control and IKZF1+/- cells with increasing concentrations of prednisolone in the presence or absence of AKT inhibitor MK2206 (21). Indeed, silencing of AKT activity partially re-sensitized IKZF1+/- cells to prednisolone treatment (Figure 1B and Supplemental Table 4). We confirmed our observations using uprosertib (GSK2141795) (22), a structurally unrelated AKT inhibitor which is under clinical evaluation for a variety of cancer types (23, 24). To confirm that AKT inhibition enhanced the prednisolone induced cell killing we used Western blot to test for PARP cleavage on protein extracts from cells exposed to prednisolone in the presence or absence of AKT inhibitors. Similar to what we observed using the amine staining, the addition of either inhibitor led to an increase apoptosis in both wildtype and knockout cells. Although the wildtype cells responded faster to treatment, longer exposure to the drugs resulted in an increased PARP cleavage in the IKZF1 deficient cells, which was further substantiated by AKT inhibition by MK2206 or Uprosertib (Figure 1C and Supplemental Figure 2B).

To further explore the effects of AKT inhibition on GC-dependent target gene regulation, quantitative reverse transcription PCR (qRT-PCR) was performed on a subset of established GC response genes, including TSC22D3, ZFP36L2 and SHKI (7). Incubation of control and IKZF1+/- cells with uprosertib enhanced the expression levels of all these response genes in wild-type SEM cells (Figure 1D and Supplemental Table 5). More importantly, we observed that the attenuated transcriptional response to prednisolone, that we observed in
FIGURE 1

(A) Immunoblot analysis of protein expression in SEM IKZF1 knockout cells generated by CRISPR/Cas9-based targeting of the IKZF1 locus. Representative blot of three independent experiments. Protein expression was quantified, normalized and tested for differences using a student’s t-test. p-values are plotted in Supplemental Figure 2A.

(B) Cell death as determined by quantification of cells positive for amine-reactive dyes using flow cytometry in SEM wt and SEM IKZF1-/- cells after a 4-day treatment with increasing concentrations of prednisolone in the presence or absence of 1 μM MK2206 or uprosertib. Each data point represents a mean (± Standard Error of the Mean (SEM)) of 3 independent experiments. The area under the curve (AUC) was determined and differences were tested for significance using an ANOVA followed by Tukey’s multiple comparisons test. P-values are plotted in Supplemental Table 4.

(C) Immunoblot analysis of protein expression in SEM wt and SEM IKZF1-/- cells after a 3 day and 5-day (for the knockout cells) treatment or 100 μg/ml prednisolone, 1 μM MK2206 or uprosertib or the combination of prednisolone with the AKT inhibitor. Representative blot of three independent experiments. Protein expression was quantified, normalized and tested for differences using an ANOVA followed by Dunnett’s multiple comparisons test. p-values are plotted in Supplemental Figure 2B.

(D) mRNA expression analysis of GR-target genes TSC22D3, ZFP36L2 and SHK1, the pro-apoptotic protein BIM and the glucocorticoid receptor NR3C1 was performed on RNA isolated SEM wt and SEM IKZF1-/- cells after a 16 hours treatment of 100 μg/ml prednisolone, 1 μM MK2206 or uprosertib or the combination of prednisolone with the AKT inhibitor. Each bar represents a mean (± SEM) of 3 independent experiments. All values were normalized to their untreated control. Differences in expression between the genotypes and between the treatment conditions were tested for significance using either a student’s t-test or ANOVA followed by Dunnett’s multiple comparisons test. p-values are listed in Supplemental Table 5. *p < 0.05; **p < 0.01; ***P < 0.001.
SEM IKZF1−/− cells, was restored by AKT inhibition (Figure 1D). Of note, similar to what has been described before (7), we found no evidence that basal expression of the glucocorticoid receptor NR3C1 was affected by loss of IKZF1.

As induction of apoptosis in response to GCs is dependent on a cell’s capacity to induce BIM expression (25, 26), we analyzed Bim mRNA expression in response to treatment with prednisolone, AKT inhibition or the combination. Indeed, prednisolone-mediated induction of Bim mRNA expression was reduced in IKZF1−/− cells relative to control cells, but could be rescued by treatment with AKT inhibitors (Figure 1D and Supplemental Table 5). We conclude from these results that GC-resistance caused by IKZF1 loss can, at least in part, be attributed to upregulation of AKT signaling, a process that can be reversed by pharmacological targeting of AKT. Given the fact that the two distinct AKT inhibitors performed highly similarly in restoring the sensitivity to prednisolone, we continued our experiments using MK2206, which is more widely tested in clinical studies.

Combined inhibition of AKT and ERK restores GC-sensitivity in IKZF1-deficient ALL cell models

Previous studies suggest that inhibition of MAPK/ERK signaling enhances GC-mediated cell killing in both B- and T-ALL cells (27, 28). For this reason, a combination of the MEK inhibitor selumetinib and dexamethasone is now under clinical investigation for the treatment of ALL (NCT03705507). Moreover, from a wide range of human cancers we know that there is extensive cross-talk between AKT and MAPK/ERK signaling (29, 30), we observed that inhibition of AKT alone resulted in partial suppression of ERK phosphorylation in both control and IKZF1−/− cells (Supplementary Figure 3C). In T-ALL dual targeting has been shown to act synergistically with prednisolone (31). Given the important role of MAPK/ERK signaling in regulating GC therapy response (27, 28), we investigated whether loss of IKZF1 affected ERK activation. Indeed, phosphorylation of ERK appeared to be elevated in IKZF1−/− cells relative to wildtype cells (Figure 2A and Supplemental Figure 4).

To assess consequences for prednisolone induced apoptosis, we treated control and IKZF1−/− cells with increasing concentrations of prednisolone in the presence or absence of AKT inhibitor MK2206, the ERK inhibitor SCH772984 or the combination thereof. Inhibition of either AKT or ERK alone enhanced prednisolone induced apoptosis in both control and IKZF1−/− cells, but this effect was strongly potentiated when both inhibitors were combined (Figure 2B and Supplemental Table 6).

Together these findings support a model in which loss of IKZF1 promotes activation of AKT as well as MAPK/ERK signaling, the latter one either independent or mediated through AKT signaling, both of which contribute to resistance to GCs in response to IKZF1 loss. More importantly, combined targeting of AKT and ERK restores GC-induced apoptosis in IKZF1−/− cells (Figure 2C).

Dual targeting of AKT and ERK signaling reverses prednisolone resistance in patient-derived xenografts in response to the IKZF1-degrading drug iberdomide

Immunomodulatory agents (IMiDs) such as lenalidomide, pomalidomide and iberdomide show efficacy in the treatment of myeloid malignancies, including acute myeloid leukemia (AML), multiple myeloma and myelodysplastic syndromes (MDS). Although the exact mechanism behind the antitumor activity remains to be established, these compounds were found to act both on the microenvironment as well as on the immune system (32, 33). On a cellular level, these compounds act as potent modulators of the Cereblon E3 ubiquitin ligase complex, and were found to redirect the E3 ubiquitin ligase complex to specific cellular targets, particularly IKZF1 and IKZF3 (34). This mechanism of action is currently exploited in the development of many other compounds to target ‘undruggable’ proteins for degradation in a new class of drugs known as proteolysis targeting chimera (PROTAC). We explored the effects of iberdomide-mediated modulation of IKZF1 protein levels on therapy responses in primary patient cells that were previously expanded using xenotransplantation in immunodeficient mice (PDX) wild type for IKZF1. This allowed us to compare the effects of IKZF1 loss in primary patient cells that are hard to genetically manipulate as they cannot be cultured ex vivo.

PDX samples wildtype for IKZF1 were exposed ex vivo to different doses of iberdomide for 24 hours, prior to analyzing their response to prednisolone. Indeed, we observed that treatment with iberdomide led to a downregulation of IKZF1 protein expression (Figures 3A, B). Although we could not detect pAKT in PDX samples, iberdomide treatment resulted in a measurable increase in ERK phosphorylation (Figure 3B).

More importantly, exposure to iberdomide phenocopied the effects of genomic loss of IKZF1 by inducing resistance to prednisolone in 8 out of 9 PDXs wildtype for IKZF1 (Figure 3C).

To assess consequences for prednisolone induced apoptosis, we treated control and iberdomide treated cells of PDX-9, the sample in which iberdomide treatment induced the strongest prednisolone resistance, with increasing concentrations of prednisolone in the presence or absence of the AKT inhibitor MK2206, ERK inhibitor SCH772984 or a combination thereof. Notably, AKT inhibition as a single agent produced little effect on prednisolone-induced apoptosis, whereas ERK inhibition strongly synergized with prednisolone treatment in both iberdomide-
treated and non-treated cells. Combining ERK and AKT inhibition, these cytotoxic effects were strongly enhanced. Even at the lowest prednisolone concentration (0.0005ug/ml), reduced cell viability was observed in both control and iberdomide treated samples when AKT and ERK signaling pathways were inhibited (Figure 3D). Notable exceptions were t(1;19) (TCF3-PBX1) rearranged leukemias, in which iberdomide-induced IKZF1 loss led to opposite effects, causing resistance to GCs (Supplementary Figure 5). Consistent with this observation, AKT inhibition rendered t(1;19) positive PDXs more resistant to GC-therapy (data not shown). Although this discrepancy awaits further explanation, it points to a unique biology for t(1;19)-positive ALL.

IKZF1-deficient ALL can be re-sensitized to prednisolone treatment by combined AKT/ERK inhibition

Next, we investigated to what extent either AKT inhibition or ERK inhibition, and a combination thereof, could increase the ex vivo sensitivity for prednisolone in BCP-ALL PDXs harboring an endogenous IKZF1 gene deletion (Figure 4A). First, the prednisolone response was tested in a panel of 21 ALL PDXs, derived from samples obtained at diagnosis, that were either wildtype for IKZF1 (n=13) or IKZF1-deficient (n=8). Cells were incubated with increasing concentrations of prednisolone and
after 3 days, cell viability was measured by staining with amine reactive dyes and quantified by flow cytometry. Data were plotted as dose-response curves and the area under the curve (AUC) was calculated as measure for sensitivity. In accordance with previous published data (7) IKZF1-deficient PDXs on average were more resistant to prednisolone compared to PDXs wild type for IKZF1, albeit with a large variation in sensitivity (Figure 4B).
Upon inhibition of either AKT or ERK signaling, prednisolone-induced apoptosis was generally potentiated in IKZF1-deficient PDXs (Figure 4C and Supplementary Figure 6). However, the extent was highly variable between PDX samples and in general inhibition of ERK signaling was more effective in restoring GC sensitivity as compared to that of AKT inhibition, but also more active as single agent. However, in all IKZF1-deficient PDXs, a combination of both inhibitors strongly increased prednisolone-induced apoptosis, again highlighting the potential of combined AKT and ERK inhibition as a therapeutic option to re-sensitize this high-risk patient group to prednisolone treatment.

Discussion

In this study we showed that IKZF1-mediated regulation of AKT and ERK signaling contributes to GC resistance in BCP-ALL. Loss of IKZF1 function leads to activation of AKT as well as MAPK/ERK signaling, resulting in GC treatment resistance. Combined inhibition of MAPK/ERK and AKT signaling restores GC-induced apoptosis in IKZF1<sup>++/-</sup> cells. This sensitizing effect is observed in BCP-ALL cell lines and PDXs. Similar to T-ALL (14), IKZF1 may act to suppress AKT signaling in BCP-ALL leading to increased AKT signaling in response to IKZF1 loss, thereby inducing GC resistance by repression of GC-induced transcriptional responses. At the same time, ERK phosphorylation appears to be induced, either by crosstalk with AKT signaling or another, yet unknown IKZF1-mediated mechanism. Inhibition of both pathways may represent a potential Achilles’ heel for GC resistance in IKZF1 deficient tumors. The availability of clinical grade small molecule inhibitors for both pathways would in principle allow a rapid translation to the clinic (35, 36). The challenge will be to combine these agents at clinically effective doses while mitigating toxicities associated with these drugs, such as rash and diarrhea (37, 38).

Another challenge remaining is to distinguish responders from non-responders. Although in the majority of IKZF1 deficient PDXs, prednisolone-induced apoptosis was potentiated by either AKT inhibition, ERK inhibition or their combination, the extent of synergy varied between patient samples. This might partially be explained by other co-occurring genetic lesions as the effects IKZF1 deletions on outcome are dependent on other co-occurring genetic events (39). For instance, BTG1 deletions (40) or the so called IKZF1<sup>+</sup> group (IKZF1 deletions co-occurring with deletions in CDKN2A, CDKN2B, PAX5, or PAR1 in the absence of ERG deletions) (41) enhance the negative impact of IKZF1 deletions on outcome.
whereas ERG deletions abrogate this effect \((42)\). However, in our small sample set, the \(I\kappaZF1^\text{plus}\) group (PDX-I4, PDX-15, PDX-I3, PDX-I2) displayed no correlation with response to AKT/ERK inhibition. Interestingly, the only PDX completely unresponsive to AKT inhibition (PDX-I5, Supplemental Figure 6) was a BCR-ABL1 positive leukemia that also harbored a TP53 deletion. This tumor suppressor is known to affect cancer metabolism and, consequently, the way tumor cells respond to treatment \((43–46)\), which may explain its unresponsiveness to AKT inhibition. The fact that most, but not all tumors respond to this combination treatment suggest that a personalized medicine approach, possibly guided by ex-vivo drug testing of primary patient samples may be used to identify and treat patients that may benefit from this treatment.

In summary our study identified increased activation of both AKT and ERK signaling pathways as drivers of GC resistance in \(I\kappaZF1\)-deficient leukemic cells, while by combined pharmacological inhibition of both pathways GC resistance could be effectively reversed. As inhibitors for both pathways are under clinical investigation, their combined use may enhance the efficacy of prednisolone in this high-risk patient group.

Data availability statement

Requests to access the datasets should be directed to FN.vanLeeuwen@prinsesmaximacentrum.nl.

Ethics statement

The studies involving human participants were reviewed and approved by I-BFM-SG: The AIEOP-BFM study group (Austria, Germany, Italy and Switzerland), the FRALLE study group (France) and the United Kingdom (UK) National Cancer Research Institute (NCRI) Childhood Cancer and Leukemia Group and DOCCG Group. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

The animal study was reviewed and approved by Dutch Central Authority for Scientific Procedures on Animals and the Animal Welfare Body of the Radboud university medical center.

Author contributions

FvL, LvdM, and BS conceptualized the project and supervised the work. MB and BV performed the experiments with assistance from RM, DvIS, JvdZ, and LJ. DvIS generated the xenografts, JM supervised JvdZ. MB, LvdM, and FvL drafted the manuscript which was edited, reviewed and approved by all authors.

Funding

This work was supported in part by research funding from the Dutch Cancer Society (KWF) (grant #10072 and #11249) and from KiKa (grant #333), and a young investigator grant from Radboudumc (MB).

Acknowledgments

We are thankful to Didier Trono for providing psPAX2 (Addgeneplasmid # 12260) and pMD2.G (# 12259) plasmids and to Benjamin Ebert for sharing the pL-CRISPR.EFS.GFP (#57818) and pLKO5.sgRNA.EFS.tRFP (#57823) plasmids. In addition, we want to thank the members of the PRIME department of the Radboud umc animal facility for valuable technical support.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.905665/full#supplementary-material

**SUPPLEMENTARY FIGURE 1**

(A) CRISPR/Cas9 was used to target the exon 3 locus of the \(I\kappaZF1\) gene in the SEM cells. After clonal expansion, the genomic DNA was analyzed by Sanger sequencing, revealing two insertions: c.del 51_86 CCCCCCTGTAAGCGATACTCC-AGATGAGGGCGATGA and c.del 149_154 ACAGAG. (B) Analysis of mRNA sequencing data revealed that the genomic deletions resulted aberrant mRNA mRNA splicing and as a consequence, absence of detectable protein \(I\).

**SUPPLEMENTARY FIGURE 2**

(A) Quantification of phospho-AKT, normalized for total AKT protein expression in SEM cells wildtype or deficient for \(I\kappaZF1\). The western blot results for 3 independent experiments were quantified, normalized and
plotted. Differences were tested for significance using a student’s t-test.

(B) Quantification of cleaved PARP protein. normalized for total PARP protein expression in SEM cells wildtype or deficient for IKZF1 exposed to prednisolone in the presence or absence of AKT inhibitors. Differences were tested for significance using ANOVA followed by Dunnett’s multiple comparisons test.

SUPPLEMENTARY FIGURE 3

(A) Schematic overview representing the workflow used to analyze protein expression of wild-type (WT) and ikzf1+/- mouse splenic B cells after ex-vivo treatment with prednisolone. Splenocytes were isolated and pre-stimulated by lipopolysaccharide (LPS) for 48h, thereafter viable cells were enriched by a Ficoll gradient. Cells were then incubated for 48h with 1 μg/ml prednisolone and protein samples were taken for immunoblot analysis. (B) Immunoblot analysis of AKT and pAKT protein expression levels of LPS-activated B cells obtained from 4 mice (2 wildtype versus 2 ikzf1+/- mice). Actin was used as a loading control.

(C) Immunoblot analysis of protein expression in SEM wt and SEM IKZF1+/- cells after a 3d treatment of 1 μM MK2206.

SUPPLEMENTARY FIGURE 4

Quantification of phospho-ERK, normalized for total ERK protein expression in SEM cells wildtype or deficient for IKZF1. The western blot results for 3 independent experiments were quantified, normalized and plotted. Differences were tested for significance using a student’s t-test.

SUPPLEMENTARY FIGURE 5

Effect of rapamycin on cell viability in ALL-PDXs carrying a heterozygous deletion of IKZF1 after a 3 day treatment with increasing concentrations of prednisolone in the presence or absence of 1 μM MK2206, SCH772984 or their combination.

References

1. Pierro J, Hogan LE, Bhatia T, Carrell WL. New targeted therapies for relapsed pediatric acute lymphoblastic leukemia. Expert Rev Anticancer Ther (2017) 17:725–36. doi: 10.1080/14737310.2017.1347507

2. Bhoywadi D, Pui CH. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol (2013) 14:e205–17. doi: 10.1016/S1470-2045(12)70580-6

3. Oskarsson T, Soderhall S, Arvidson J, Forestier E, Montgomery S, Bottai M, et al. Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome. Haematologica (2016) 111:68–76. doi: 10.3324/haematol.2015.131660

4. Kruseman HA, et al. Copy number alterations in b-cell development genes, drug resistance, and clinical outcome in pediatric b-cell precursor acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia (2010) 24:265–84. doi: 10.1038/leu.2009.257

5. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 360:470–80. doi: 10.1056/NEJMoa0808253

6. Churchman ML, Evans K, Richmond J, Robbins A, Jones L, Shapiro JM, et al. Synergem of FAK and tyrosine kinase inhibition in ph(+) ALL. JCI Insight (2016) 1. doi: 10.1172/jci.insight.86982

7. Marke R, Havinga J, Cloos J, Demkes M, Poelmans G, Yuniati L, et al. Tumor suppressor IKZF1 mediates glucocorticoid resistance in b-cell precursor acute lymphoblastic leukemia. Leukemia (2016) 30:1599–603. doi: 10.1038/leu.2015.359

8. Imaizumi T, Yano M, Asai D, Motrya-Saito A, Suenobu SH, Hasegawa D, et al. IKZF1 deletion is enriched in pediatric b-cell precursor acute lymphoblastic leukemia patients showing prednisolone resistance. Leukemia (2016) 30:1801–3. doi: 10.1038/leu.2016.128

9. Stegha EMP, Boer JM, Hoogkamer AQ, Boeree A, de Haas V, de Groot-Kruiseman HA, et al. Copy number alterations in b-cell development genes, drug resistance, and clinical outcome in pediatric b-cell precursor acute lymphoblastic leukemia. Sci Rep (2019) 9:4634. doi: 10.1038/s41598-019-41078-4

10. Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol (2010) 11:1096–106. doi: 10.1016/S1470-2045(10)70114-5

11. Pieters R, de Groot-Kruiseman H, van der Velden V, Focco M, Berg Hvd, Bont E, et al. Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring. Study ALL10 from the Dutch childhood oncology group. J Clin Oncol (2016) 34:2591–501. doi: 10.1200/JCO.2015.64.6364

12. Gao J, Liu WJ. Prognostic value of the response to prednisone for children with acute lymphoblastic leukemia: a meta-analysis. Eur Rev Med Pharmacol Sci (2018) 22:7858–66. doi: 10.26355/eurrev_201811_16411

13. Moricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia (2010) 24:265–84. doi: 10.1038/leu.2009.257

14. Dovat E, Song C, Hu T, Rahman MA, Dhanayamraj PK, Klink M, et al. Transcriptional regulation of PIK3CD and PIKIFYVE in T-cell acute lymphoblastic leukemia by IKAROS and protein kinase CK2. Int J Mol Sci (2021) 22. doi: 10.3390/ijms22020819

15. Piovon E, Yu J, Tesolvo V, Herranz D, Ambesi-Impiombato A, Da Silva AC, et al. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer Cell (2013) 24:766–76. doi: 10.1016/j.ccr.2013.10.022

16. Wei G, Twomey D, Lamb J, Schis K, Agarwal J, Stam RW, et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell (2006) 10:331–42. doi: 10.1016/j.ccr.2006.09.006

17. Meyer LK, Delgado-Martin C, Maude SL, Shannon KM, Teachey DT, Herriman M. CRLF2 rearrangement in ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or akt inhibition. PloS One (2019) 14:e0220026. doi: 10.1371/journal.pone.0220026

18. Schmits M, Breithaupt P, Schiedegger N, Cario G, Bonapace L, Meissner R, et al. Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemic compartment. Blood (2011) 118:1854–64. doi: 10.1182/blood-2011-03-328039

19. Frisvantoa V, Dohuy MP, Rinaldii A, Tchinda J, Dunn SH, Kanz J, et al. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood (2017) 129:e26–37. doi: 10.1182/blood-2016-738070

20. Mihara K, Imai C, Coustan-Smith E, Dome JS, Dominici M, Vanin E, et al. Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase. Br J Haematol (2003) 120:846–9. doi: 10.1046/j.1365-2457.2003.02417.x

21. Hitari H, Sootome Y, Nakaturasu Y, Miyama K, Taguchi S, Tsujioka J, et al. MK-2206, an allosteric akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther (2010) 9:1956–67. doi: 10.1158/1535-7163.MCT-09-1012

22. Dumbble M, Crouchman MC, Zhang SY, Schaber M, Levy D, Rebell K, et al. Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor. PloS One (2014) 9:e1010880. doi: 10.1371/journal.pone.0100880

23. Aghajanian C, Bell-McGuinn KM, Burris HA3rd, Sui LL, Stayern LA, Wheeler JJ, et al. A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors. Invest New Drugs (2018) 36:1016–25. doi: 10.1007/s10637-018-0591-z

24. Gungor H, Saleem A, Babar S, Dina R, El-Bahrawy MA, Curry E, et al. Dose-finding quantification of phospho-ERK, normalized for total ERK protein expression in SEM cells wildtype or deficient for IKZF1. The western blot results for 3 independent experiments were quantified, normalized and plotted. Differences were tested for significance using a student’s t-test.
25. Brown JA, Fernando A. Glucocorticoid resistance in acute lymphoblastic leukemia: BIM finally. Cancer Cell (2018) 34:869–71. doi: 10.1016/j.ccell.2018.11.011

26. Tocsan CE, Jing D, Mayoh C, Lock RB. Reversal of glucocorticoid resistance in paediatric acute lymphoblastic leukaemia is dependent on restoring BIM expression. Br J Cancer (2020) 122:1769–81. doi: 10.1038/s41416-020-0824-8

27. van der Zwart JG, Buijs-Gradlnnes J, Ceardo V, Debets DO, Smits WK, Chen Z, et al. MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance. Leukemia (2021) 35:3394–405. doi: 10.1038/s41375-021-01291-5

28. Ley R, Ewing KS, Hadfield K, Cook SJ. Regulatory phosphorylation of bim: Sorting out the ERK from the JNK. Frontiers in Oncology (2020) 10.3389/fonc.2020.515198

29. Cao Z, Liou Q, Su M, Huang K, Jin J, Cao D. AKT and ERK dual inhibitors: The way forward? Cancer Lett (2019) 459:30–40. doi: 10.1016/j.canlet.2019.05.025

30. Aksamitiene E, Kiyatkin A, Khodolenko BN. Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: A fine balance. Biochem Soc Trans (2012) 40:139–46. doi: 10.1042/BST2011069

31. Cante-Barrett K, Speiwers-Hagelstein JA, Buijs-Gladlnnes JG, Uitdehaag JC, Smits WK, van der Zwert J, et al. MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia. Leukemia (2016) 30:1832–43. doi: 10.1038/leu.2016.83

32. Piccolomo A, Schiufene CP, Strafella V, Specchia G, Musto P, Albano F. Immunomodulatory drugs in acute myeloid leukemia treatment. Cancers (Basel) (2020) 12:92528. doi: 10.3390/cancers12092528

33. Fuchs O. Treatment of lymphoma and myeloid malignancies by immunomodulatory drugs. Cardiourac Hematol Disord Drug Targets (2019) 19:51–78. doi: 10.2174/1871529X18666180522073855

34. Kronke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, et al. Lenalodnide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science (2014) 343:301–5. doi: 10.1126/science.1244851

35. Shariati M, Meric-Bernstam F. Targeting AKT for cancer therapy. Expert Opin Investig Drugs (2019) 28:977–88. doi: 10.1080/13543874.2019.1676726

36.Degirmenci U, Wang M, Hu J. Targeting aberrant RAS/RAF/MEK/ERK signaling for cancer therapy. Cells (2020) 9(1):198. doi: 10.3390/cells9010198

37. Tolcher AW, Kurzrock R, Valero V, Gonzalez R, Heist RS, Tan AR, et al. Phase I dose-escalation trial of the oral Akt inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. Cancer Chemother Pharmacol. (2020) 85:673–83. doi: 10.1007/s00058-020-04038-8

38. Tolcher AW, Khan K, Ong M, Banerji U, Papadimitrakopoulos V, Gandara DR, et al. Antitumor activity in RAS-driven tumors by blocking Akt and MEK. Clin Cancer Res (2015) 21:739–48. doi: 10.1158/1078-0432.CCR-14-1901

39. Marke R, van Leeuwen FN, Scheijen B. The many faces of IKZF1 in b-cell precursor acute lymphoblastic leukemia. Haematologica (2018) 103:565–74. doi: 10.3324/haematol.2017.185603

40. Scheijen B, Boer JM, Marke R, Tjchon E, van Ingen Schenau D, Waanders E, et al. Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in b-cell precursor acute lymphoblastic leukemia patients. Haematologica (2017) 102:541–51. doi: 10.3324/haematol.2016.150023

41. Stanulla M, Dagdan E, Zalova M, Moricke A, Palmi C, Cazzaniga G, et al. IKZF1(plus) defines a new minimal residual disease-dependent very poor prognostic profile in pediatric b-cell precursor acute lymphoblastic leukemia. J Clin Oncol (2018) 36:1240–9. doi: 10.1200/JCO.2017.74.3617

42. Clappier E, Auclerc MF, Rapion J, Bakkus MM, Caye A, Khemiri A, et al. An intragenic ERG deletion is a marker of an oncogenic subtype of b-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions. Leukemia (2018) 28:70–7. doi: 10.1038/leu.2017.277

43. Kim J, DeBerardinis RJ. Mechanisms and implications of metabolic heterogeneity in cancer. Cell Metab (2019) 30:434–46. doi: 10.1016/j.cmet.2019.08.013

44. Borroughs KJ, DeBerardinis RJ. Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol (2015) 17:351–9. doi: 10.1038/ncb3124

45. Palm W, Thompson CB. Nutrient acquisition strategies of mammalian cells. Nature (2017) 546:344–42. doi: 10.1038/nature22379

46. Olivas-Aguirre M, Torres-Lopez L, Potossin I, Dobrovinskaya O. Overcoming glucocorticoid resistance in acute lymphoblastic leukemia. Repurposed drugs can improve the protocol. Front Oncol (2021) 11:617937. doi: 10.3389/fonc.2021.617937